These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. Duvic M; Hymes K; Heald P; Breneman D; Martin AG; Myskowski P; Crowley C; Yocum RC; J Clin Oncol; 2001 May; 19(9):2456-71. PubMed ID: 11331325 [TBL] [Abstract][Full Text] [Related]
3. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC; Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336 [TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas. Hamada T; Sugaya M; Tokura Y; Ohtsuka M; Tsuboi R; Nagatani T; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Yoshida T; Saida T; Iwatsuki K J Dermatol; 2017 Feb; 44(2):135-142. PubMed ID: 27543197 [TBL] [Abstract][Full Text] [Related]